While diet and exercise remain the foundation for many, more and more stars are openly admitting to using weight-loss ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...

Serena Williams opens up about her weight loss struggles and the use of GLP-1 medications, highlighting issues of access and ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with ...

This is all you need to know about the new weight loss jab 'Reta' that's said to be 3 times stronger than Ozempic.

Christina Aguilera is stunning in her retro bikini and high heels as she hits the ice cream truck amid her Ozempic rumors.